{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:40:45Z","timestamp":1785786045018,"version":"3.56.0"},"reference-count":285,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Serotonin modulates several physiological and cognitive pathways throughout the human body that affect emotions, memory, sleep, and thermal regulation. The complex nature of the serotonergic system and interactions with other neurochemical systems indicate that the development of depression may be mediated by various pathomechanisms, the common denominator of which is undoubtedly the disturbed transmission in central 5-HT synapses. Therefore, the deliberate pharmacological modulation of serotonergic transmission in the brain seems to be one of the most appropriate strategies for the search for new antidepressants. As discussed in this review, the serotonergic system offers great potential for the development of new antidepressant therapies based on the combination of SERT inhibition with different pharmacological activity towards the 5-HT system. The aim of this article is to summarize the search for new antidepressants in recent years, focusing primarily on the possibility of benefiting from interactions with various 5-HT receptors in the pharmacotherapy of depression.<\/jats:p>","DOI":"10.3390\/ijms22169015","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:47:52Z","timestamp":1629668872000},"page":"9015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["5-HT Receptors and the Development of New Antidepressants"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-0567","authenticated-orcid":false,"given":"Grzegorz","family":"\u015alifirski","sequence":"first","affiliation":[{"name":"Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Kr\u00f3l","sequence":"additional","affiliation":[{"name":"Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Tur\u0142o","sequence":"additional","affiliation":[{"name":"Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"Eriksson","year":"2008","journal-title":"Behav. Brain Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/npp.2011.85","article-title":"Epigenetic Treatments for Cognitive Impairments","volume":"37","author":"Day","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jad.2017.02.029","article-title":"Restoring function in major depressive disorder: A systematic review","volume":"215","author":"Sheehan","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2011.02.003","article-title":"5-HT and depression: Is the glass half-full?","volume":"11","author":"Sharp","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1017\/S0033291714000221","article-title":"Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): An example from the GENPOD trial","volume":"44","author":"Wiles","year":"2014","journal-title":"Psychol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0893-133X(00)00220-7","article-title":"Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects","volume":"24","author":"Turcotte","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/15622970701227829","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care","volume":"8","author":"Bauer","year":"2007","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","article-title":"How do antidepressants work? New perspectives for refining future treatment approaches","volume":"4","author":"Harmer","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Kumar, R., and Bungau, S. (2021). Integrating Endocannabinoid Signalling In Depression. J. Mol. Neurosci.","DOI":"10.1007\/s12031-020-01774-7"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Sharma, N., and Bungau, S. (2021). Elucidating the Possible Role of FoxO in Depression. Neurochem. Res.","DOI":"10.1007\/s11064-021-03364-4"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s11064-021-03307-z","article-title":"Exploring Sonic Hedgehog Cell Signaling in Neurogenesis: Its Potential Role in Depressive Behavior","volume":"46","author":"Rana","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rana, T., Behl, T., Sehgal, A., Srivastava, P., and Bungau, S. (2020). Unfolding the Role of BDNF as a Biomarker for Treatment of Depression. J. Mol. Neurosci.","DOI":"10.1007\/s12031-020-01754-x"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S1461145712001496","article-title":"On \u201cpolypharmacy\u201d and multi-target agents, complementary strategies for improving the treatment of depression: A comparative appraisal","volume":"17","author":"Millan","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nchembio.1547","article-title":"Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth","volume":"10","author":"Duhr","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lfs.2018.08.050","article-title":"Serotonin receptors in depression and anxiety: Insights from animal studies","volume":"210","author":"Sapa","year":"2018","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.biopsych.2013.03.021","article-title":"Brain Serotonin 1A Receptor Binding as a Predictor of Treatment Outcome in Major Depressive Disorder","volume":"74","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","article-title":"The 5-HT1A receptor in Major Depressive Disorder","volume":"26","author":"Kaufman","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.euroneuro.2013.04.013","article-title":"Developments in the field of antidepressants, where do we go now?","volume":"25","author":"Artigas","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00441-018-2978-8","article-title":"Monoaminergic system and depression","volume":"377","author":"Mico","year":"2019","journal-title":"Cell Tissue Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: Signaling to behavior","volume":"161","author":"Albert","year":"2018","journal-title":"Biochimie"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.2174\/1570159X17666190811161807","article-title":"Targeting Serotonin1A Receptors for Treating Chronic Pain and Depression","volume":"17","author":"Haleem","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.euroneuro.2017.10.032","article-title":"Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies","volume":"28","author":"Artigas","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1017\/S0033291713002857","article-title":"Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: Systematic review and meta-analysis","volume":"44","author":"Kishi","year":"2014","journal-title":"Psychol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","article-title":"The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder","volume":"11","author":"Sahli","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1517\/14656566.2014.960842","article-title":"A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine","volume":"15","author":"Grossberg","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcp.21533","article-title":"What do we know about serotonin?","volume":"217","author":"Jonnakuty","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Banerjee, P., Mehta, M., and Kanjilal, B. (2007). The 5-HT1A Receptor: A Signaling Hub Linked to Emotional Balance, CRC Press\/Taylor & Francis. Chapter 7.","DOI":"10.1201\/9781420005752.ch7"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1569-7339(10)70078-3","article-title":"Tryptophan Hydroxylase and Serotonin Synthesis Regulation","volume":"Volume 21","author":"Hasegawa","year":"2010","journal-title":"Handbook of Behavioral Neuroscience"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/ctg.2012.8","article-title":"Serotonin and GI Disorders: An Update on Clinical and Experimental Studies","volume":"3","author":"Manocha","year":"2012","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT1A receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0074-7742(05)64005-6","article-title":"Section V. Serotonin System","volume":"64","author":"Smythies","year":"2005","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1046\/j.1471-4159.2001.00536.x","article-title":"Study of the brain serotonergic system with labeled \u03b1-methyl-l-tryptophan","volume":"78","author":"Diksic","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1523\/JNEUROSCI.21-24-09917.2001","article-title":"Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors","volume":"21","author":"Celada","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.euroneuro.2006.06.012","article-title":"The role of noradrenergic tone in the dorsal raphe nucleus of the mouse in the acute behavioral effects of antidepressant drugs","volume":"17","author":"Bechtholt","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0306-4522(01)00294-9","article-title":"Evidence for a role of GABA interneurones in the cortical modulation of midbrain 5-hydroxytryptamine neurones","volume":"106","author":"Varga","year":"2001","journal-title":"Neuroscience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1471-4159.2001.00275.x","article-title":"Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus","volume":"77","author":"Ugedo","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ohno, Y. (2019). Serotonin Receptors as the Therapeutic Target for Central Nervous System Disorders, Elsevier Inc.","DOI":"10.1016\/B978-0-12-800050-2.00018-8"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A","article-title":"Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain","volume":"417","author":"Riad","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16444","DOI":"10.1074\/jbc.274.23.16444","article-title":"Stimulation of cAMP synthesis by G(i)-coupled receptors upon ablation of distinct G\u03b1(i) protein expression. G(i) subtype specificity of the 5-HT1A receptor","volume":"274","author":"Liu","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/neu.20321","article-title":"Gender-dependent regulation of G-protein-gated inwardly rectifying potassium current in dorsal raphe neurons in knock-out mice devoid of the 5-hydroxytryptamine transporter","volume":"66","author":"Loucif","year":"2006","journal-title":"J. Neurobiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1460-9568.1992.tb00861.x","article-title":"GABAergic Interneurons are the Major Postsynaptic Targets of Median Raphe Afferents in the Rat Dentate Gyrus","volume":"4","author":"Halasy","year":"1992","journal-title":"Eur. J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(95)00241-A","article-title":"Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications","volume":"69","author":"Cassel","year":"1995","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbr.2008.02.037","article-title":"Modulation of cholinergic functions by serotonin and possible implications in memory: General data and focus on 5-HT1A receptors of the medial septum","volume":"195","author":"Koenig","year":"2008","journal-title":"Behav. Brain Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/138161210790361416","article-title":"Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex","volume":"16","author":"Artigas","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0079-6123(08)00902-3","article-title":"Serotonin control of central dopaminergic function: Focus on in vivo microdialysis studies","volume":"172","author":"Pierucci","year":"2008","journal-title":"Prog. Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1113\/jphysiol.1987.sp016862","article-title":"Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro","volume":"394","author":"Andrade","year":"1987","journal-title":"J. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: Preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","year":"2011","journal-title":"Neuropsychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1471-4159.2007.04448.x","article-title":"Plasticity of 5-HT1A receptor-mediated signaling during early postnatal brain development","volume":"101","author":"Mehta","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1460-9568.2005.03904.x","article-title":"Coupling of 5-HT1A autoreceptors to inhibition of mitogen-activated protein kinase activation via G\u03b2\u03b3 subunit signaling","volume":"21","author":"Kushwaha","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuropharm.2005.05.001","article-title":"Differential ion current activation by human 5-HT1A receptors in Xenopus oocytes: Evidence for agonist-directed trafficking of receptor signalling","volume":"49","author":"Heusler","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S1461145709990940","article-title":"Agonist-dependent modulation of G-protein coupling and transduction of 5-HT1A receptors in rat dorsal raphe nucleus","volume":"13","author":"Castro","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15049","DOI":"10.1073\/pnas.95.25.15049","article-title":"Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice","volume":"95","author":"Heisler","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pharep.2015.08.007","article-title":"The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect","volume":"68","author":"Pytka","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","article-title":"Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: In-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Bardin","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2017.06.032","article-title":"HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels","volume":"333","author":"Pytka","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113082","DOI":"10.1016\/j.bbr.2020.113082","article-title":"NLX-101, a highly selective 5-HT1A receptor biased agonist, mediates antidepressant-like activity in rats via prefrontal cortex 5-HT1A receptors","volume":"401","author":"Auclair","year":"2021","journal-title":"Behav. Brain Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-4-21","article-title":"Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness","volume":"4","author":"Albert","year":"2011","journal-title":"Mol. Brain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109681","DOI":"10.1016\/j.mehy.2020.109681","article-title":"Is the bell-shaped dose-response curve of the selective serotonin reuptake inhibitor due to 5-HT1A auto-receptors?","volume":"140","author":"Terao","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0893-133X(00)00175-5","article-title":"Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635","volume":"24","author":"Romero","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-6147(00)01682-5","article-title":"How does pindolol improve antidepressant action?","volume":"22","author":"Artigas","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF00166940","article-title":"Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat","volume":"347","author":"Celada","year":"1993","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","article-title":"Current advances and trends in the treatment of depression","volume":"15","author":"Blier","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0893-133X(95)00240-E","article-title":"Effect of pindolol on the function of pre- and postsynaptic 5-HT(1A) receptors: In vivo microdialysis and electrophysiological studies in the rat brain","volume":"15","author":"Romero","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.npp.1300686","article-title":"Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain","volume":"30","author":"Chouvet","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2174\/187152410791196341","article-title":"New Insight into the Therapeutic Role of 5-HT1A Receptors in Central Nervous System Disorders","volume":"10","author":"Ohno","year":"2010","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuron.2009.12.003","article-title":"5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants","volume":"65","author":"Craige","year":"2010","journal-title":"Neuron"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0269881108097714","article-title":"Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: A systematic review","volume":"24","author":"Whale","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002130000470","article-title":"Partial 5-HT(1A) receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo","volume":"151","author":"Arborelius","year":"2000","journal-title":"Psychopharmacology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication Augmentation after the Failure of SSRIs for Depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/YIC.0000000000000271","article-title":"Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study","volume":"34","author":"Vieta","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.biopsych.2008.06.027","article-title":"Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder","volume":"64","author":"MacQueen","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1176\/ajp.157.1.115","article-title":"Hippocampal volume reduction in major depression","volume":"157","author":"Bremner","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/WNR.0000000000000165","article-title":"Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression","volume":"25","author":"Hong","year":"2014","journal-title":"Neuroreport"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Banerjee, R., Ghosh, A.K., Ghosh, B., Bhattacharyya, S., and Mondal, A.C. (2013). Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: An analysis in human postmortem brain. Clin. Med. Insights Pathol., 1\u201311.","DOI":"10.4137\/CPath.S12530"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuroscience.2014.12.048","article-title":"Chronic unpredictable mild stress decreases BDNF and NGF levels and Na+,K+-ATPase activity in the hippocampus and prefrontal cortex of mice: Antidepressant effect of chrysin","volume":"289","author":"Filho","year":"2015","journal-title":"Neuroscience"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbr.2010.02.026","article-title":"Long-term treatment with peony glycosides reverses chronic unpredictable mild stress-induced depressive-like behavior via increasing expression of neurotrophins in rat brain","volume":"210","author":"Mao","year":"2010","journal-title":"Behav. Brain Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jep.2014.01.006","article-title":"Antidepressant-like effects of Xiaochaihutang in a rat model of chronic unpredictable mild stress","volume":"152","author":"Su","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejphar.2016.07.042","article-title":"Hesperidin reverses cognitive and depressive disturbances induced by olfactory bulbectomy in mice by modulating hippocampal neurotrophins and cytokine levels and acetylcholinesterase activity","volume":"789","author":"Antunes","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"44","DOI":"10.55782\/ane-2014-1971","article-title":"Curcumin and sertraline prevent the reduction of the number of neurons and glial cells and the volume of rats\u2019 medial prefrontal cortex induced by stress","volume":"74","author":"Noorafshan","year":"2014","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1476-5381.1993.tb12859.x","article-title":"Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors","volume":"108","author":"Luscombe","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/nn.4116","article-title":"5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response","volume":"18","author":"Samuels","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1523\/JNEUROSCI.5836-10.2011","article-title":"Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety","volume":"31","author":"Craige","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11967","DOI":"10.1523\/JNEUROSCI.1668-17.2017","article-title":"Abrogated Freud-1\/Cc2d1a Repression of 5-HT1A Autoreceptors Induces Fluoxetine-Resistant Anxiety\/Depression-Like Behavior","volume":"37","author":"Daigle","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1523\/JNEUROSCI.18-18-07394.1998","article-title":"Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression\u2014Postmortem evidence for decreased serotonin activity","volume":"18","author":"Stockmeier","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2005.06.016","article-title":"Altered serotonin 1A binding in major depression: A [carbonyl-C-11] WAY100635 positron emission tomography study","volume":"59","author":"Parsey","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jpsychires.2007.05.004","article-title":"Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides","volume":"42","author":"Boldrini","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1523\/JNEUROSCI.23-25-08788.2003","article-title":"Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide","volume":"23","author":"Lemonde","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/mp.2008.8","article-title":"Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression","volume":"14","author":"Neff","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.mp.4001401","article-title":"Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [ 11C]WAY-100635","volume":"9","author":"Bhagwagar","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1523\/JNEUROSCI.18-23-10150.1998","article-title":"Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT(1A) receptors","volume":"18","author":"Haddjeri","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.mp.4000712","article-title":"Adult brain neurogenesis and psychiatry a no","volume":"5","author":"Jacobs","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1124\/jpet.301.3.1144","article-title":"5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl] -1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A [11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl)-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans","volume":"301","author":"Rabiner","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1476-5381.2011.01770.x","article-title":"Preclinical and clinical characterization of the selective 5-HT1A receptor antagonist DU-125530 for antidepressant treatment","volume":"167","author":"Scorza","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Pehrson","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4068\/cmj.2016.52.2.91","article-title":"Vilazodone for the Treatment of Depression: An Update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Misztak","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0278-5846(93)90034-P","article-title":"5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action?","volume":"17","author":"Schreiber","year":"1993","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/acschemneuro.8b00661","article-title":"Serotonin 5-HT1A Receptor Biased Agonists Display Differential Anxiolytic Activity in a Rat Social Interaction Model","volume":"10","author":"Bardin","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0b013e31822c6741","article-title":"A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder","volume":"31","author":"Robinson","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2005.09.065","article-title":"5-HT1A and 5-HT1B receptor agonists and aggression: A pharmacological challenge of the serotonin deficiency hypothesis","volume":"526","author":"Koolhaas","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_110","first-page":"209","article-title":"Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications","volume":"71","author":"Naranjo","year":"1994","journal-title":"EXS"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: High-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","article-title":"Serotonin 1B receptors: From protein to physiological function and behavior","volume":"28","author":"Sari","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-2982.2007.01294.x","article-title":"Do 5HT1B\/1D Receptor Agonists have an Effect on Mood and Anxiety Disorders?","volume":"27","author":"Morelli","year":"2007","journal-title":"Cephalalgia"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Li, X., Sun, X., Sun, J., Zu, Y., Zhao, S., Sun, X., Li, L., Zhang, X., Wang, W., and Liang, Y. (2020). Depressive-like state sensitizes 5-HT1A and 5-HT1B auto-receptors in the dorsal raphe nucleus sub-system. Behav. Brain Res., 389.","DOI":"10.1016\/j.bbr.2020.112618"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-010-2097-z","article-title":"The role of serotonin receptor subtypes in treating depression: A review of animal studies","volume":"213","author":"Carr","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.npp.1300320","article-title":"Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone","volume":"29","author":"Banasr","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/npp.2016.109","article-title":"A lack of serotonin 1B autoreceptors results in decreased anxiety and depression-related behaviors","volume":"41","author":"Nautiyal","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.npp.1300000","article-title":"Substance abuse disorder and major depression are associated with the human 5-HTIB receptor gene(HTRIB) G86IC polymorphism","volume":"28","author":"Huang","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2174\/138945009789735192","article-title":"The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression (Supplementary Tables)","volume":"10","author":"Ruf","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajmg.1347","article-title":"No evidence of an association between 5HT1B receptor gene polymorphism and suicide victims in a Japanese population","volume":"105","author":"Nishiguchi","year":"2001","journal-title":"Am. J. Med. Genet. Neuropsychiatr. Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropharm.2011.01.046","article-title":"Co-expression of serotonin 5-HT1B and 5-HT4 receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum","volume":"61","author":"Egeland","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1523\/JNEUROSCI.3110-06.2007","article-title":"Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation","volume":"27","author":"Svenningsson","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.1117571","article-title":"Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States","volume":"311","author":"Svenningsson","year":"2006","journal-title":"Science"},{"key":"ref_124","first-page":"533","article-title":"Autoregulation of serotonin neurons: Role in antidepressant drug action","volume":"51","author":"Blier","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF00168834","article-title":"Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: An electrophysiological study in the rat brain","volume":"337","author":"Blier","year":"1988","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0304-3940(95)11390-I","article-title":"The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT1A and 5-HT1B D receptor antagonists","volume":"188","author":"Davidson","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00008877-200412000-00001","article-title":"Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression","volume":"15","author":"Stachowicz","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.bjp.0703297","article-title":"Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat","volume":"130","author":"Queiroz","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_129","first-page":"1083","article-title":"Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse","volume":"298","author":"Knobelman","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.neuropharm.2006.01.010","article-title":"Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]- 1-[2\u2032-methyl-4\u2032-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical","volume":"50","author":"Dawson","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1527-3458.2001.tb00209.x","article-title":"SB-236057-A: A selective 5-HT1B receptor inverse agonist","volume":"7","author":"Roberts","year":"2001","journal-title":"CNS Drug Rev."},{"key":"ref_132","first-page":"541","article-title":"Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system","volume":"33","author":"Chenu","year":"2008","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejphar.2005.04.025","article-title":"Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: A possible mechanism of action","volume":"516","author":"Stachowicz","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00213-018-4872-1","article-title":"The 5-HT1B receptor\u2014A potential target for antidepressant treatment","volume":"235","author":"Tiger","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0893-133X(96)00095-4","article-title":"Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT(1B) mRNA in a sequential manner in the rat dorsal raphe nucleus","volume":"15","author":"Neumaier","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0028-3908(99)00229-4","article-title":"The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572","volume":"39","author":"Gobert","year":"2000","journal-title":"Neuropharmacology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1192\/bjp.178.5.454","article-title":"Decreased sensitivity of 5-HTID receptors in melancholic depression","volume":"178","author":"Whale","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.mp.4000259","article-title":"5-HT(1D) and 5-HT(1E\/1F) binding sites in depressed suicides: Increased 5-HT(1D) binding in globus pallidus but not cortex","volume":"2","author":"Lowther","year":"1997","journal-title":"Mol. Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1124\/jpet.111.179606","article-title":"Toward Selective Drug Development for the Human 5-Hydroxytryptamine 1E Receptor: A Comparison of 5-Hydroxytryptamine 1E and 1F Receptor Structure-Affinity Relationships","volume":"337","author":"Klein","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(95)00104-X","article-title":"The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain","volume":"676","author":"Burnet","year":"1995","journal-title":"Brain Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1096-9861(20010122)429:4<571::AID-CNE5>3.0.CO;2-X","article-title":"Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies","volume":"429","author":"Palacios","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/acschemneuro.6b00409","article-title":"Growing Evidence for Heterogeneous Synaptic Localization of 5-HT2A Receptors","volume":"8","author":"Berthoux","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-4159.2007.04768.x","article-title":"Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT2A receptors in human and monkey prefrontal cortex","volume":"103","author":"Mengod","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.2013.769957","article-title":"5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders","volume":"22","author":"Mestre","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.pharep.2019.05.012","article-title":"Adaptive mechanisms following antidepressant drugs: Focus on serotonin 5-HT2A receptors","volume":"71","author":"Smaga","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3928\/02793695-20110203-98","article-title":"Vilazodone: Another novel atypical antidepressant drug","volume":"49","author":"Howland","year":"2011","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4065\/76.5.511","article-title":"Pharmacology of antidepressants","volume":"76","author":"Richelson","year":"2001","journal-title":"Mayo Clin. Proc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1471-4159.1993.tb13618.x","article-title":"Chronic Electroconvulsive Seizures Increase the Expression of Serotonin2 Receptor mRNA in Rat Frontal Cortex","volume":"61","author":"Butler","year":"1993","journal-title":"J. Neurochem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YCO.0b013e32831be9ef","article-title":"Augmentation strategies for treatment-resistant depression","volume":"22","author":"Carvalho","year":"2009","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10401239909147053","article-title":"Clinical Experience with Mirtazapine in the Treatment of Panic Disorder","volume":"11","author":"Carpenter","year":"1999","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.npp.1300057","article-title":"Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders","volume":"28","author":"Marek","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and In Vivo Interaction of Serotonin1A and Serotonin2A Receptors in Pyramidal Neurons of Pre-frontal Cortex","volume":"14","author":"Bortolozzi","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","article-title":"Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists","volume":"56","author":"Gray","year":"2001","journal-title":"Brain Res. Bull."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0024-3205(03)00141-3","article-title":"5-HT2A and 5-HT2C receptors and their atypical regulation properties","volume":"72","author":"Luyten","year":"2003","journal-title":"Life Sci."},{"key":"ref_156","first-page":"111","article-title":"Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam","volume":"7","author":"Bressa","year":"1987","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Blier, P., and El-Mansari, M. (2013). Serotonin and beyond: Therapeutics for major depression. Philos. Trans. R. Soc. B Biol. Sci., 368.","DOI":"10.1098\/rstb.2012.0536"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/syn.10009","article-title":"Serotonin 1A receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABAA receptors: A microiontophoretic study in the rat locus coeruleus","volume":"42","author":"Szabo","year":"2001","journal-title":"Synapse"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1017\/S1092852900001371","article-title":"Response of the norepinephrine system to antidepressant drugs","volume":"6","author":"Szabo","year":"2001","journal-title":"CNS Spectr."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.biopsych.2006.05.015","article-title":"Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain","volume":"61","author":"Dremencov","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-007-0826-8","article-title":"Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain","volume":"194","author":"Kawahara","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00213-005-2198-2","article-title":"Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: Implications for bipolar disorder","volume":"181","author":"Seager","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00213-009-1611-7","article-title":"Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder","volume":"206","author":"Chernoloz","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/npp.2012.18","article-title":"Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission","volume":"37","author":"Chernoloz","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/syn.10308","article-title":"The Highly Selective 5-Hydroxytryptamine (5-HT)2A Receptor Antagonist, EMD 281014, Significantly Increases Swimming and Decreases Immobility in Male Congenital Learned Helpless Rats in the Forced Swim Test","volume":"52","author":"Patel","year":"2004","journal-title":"Synapse"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-2999(94)90119-8","article-title":"Preclinical pharmacology of FG5893: A potential anxiolytic drug with high affinity for both 5-HT1A and 5-HT2A receptors","volume":"261","author":"Albinsson","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.09.037","article-title":"Activation of 5-HT2A receptor disrupts rat maternal behavior","volume":"128","author":"Gao","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cercor\/bhy064","article-title":"Sustained Activation of Postsynaptic 5-HT 2A Receptors Gates Plasticity at Prefrontal Cortex Synapses","volume":"29","author":"Berthoux","year":"2019","journal-title":"Cereb. Cortex"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ynstr.2017.06.001","article-title":"5-HT2A receptor deficiency alters the metabolic and transcriptional, but not the behavioral, consequences of chronic unpredictable stress","volume":"7","author":"Jaggar","year":"2017","journal-title":"Neurobiol. Stress"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0306-4522(96)00480-0","article-title":"5-Hydroxytryptamine-2B receptor protein in the rat central nervous system","volume":"76","author":"Duxon","year":"1997","journal-title":"Neuroscience"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin G protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/mp.2011.159","article-title":"5-HT 2B receptors are required for serotonin-selective antidepressant actions","volume":"17","author":"Diaz","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41386-018-0013-0","article-title":"Positive regulation of raphe serotonin neurons by serotonin 2B receptors","volume":"43","author":"Belmer","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-008-1306-5","article-title":"Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation","volume":"201","author":"Li","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euroneuro.2015.12.012","article-title":"Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants","volume":"26","author":"Diaz","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/B978-0-444-64125-0.00034-7","article-title":"Serotonin and 5-HT2B receptors in microglia control of behavior","volume":"31","author":"Maroteaux","year":"2020","journal-title":"Handb. Behav. Neurosci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2515\/therapie:2005065","article-title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies","volume":"60","author":"Millan","year":"2005","journal-title":"Therapie"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/syn.1095","article-title":"Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: Comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA","volume":"42","author":"Mengod","year":"2001","journal-title":"Synapse"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchemneu.2004.03.010","article-title":"Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei","volume":"29","author":"Serrats","year":"2005","journal-title":"J. Chem. Neuroanat."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.neuroscience.2007.02.064","article-title":"Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction","volume":"146","author":"Liu","year":"2007","journal-title":"Neuroscience"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Bubar, M.J., Stutz, S.J., and Cunningham, K.A. (2011). 5-HT2C Receptors localize to dopamine and gaba neurons in the rat mesoaccumbens pathway. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020508"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-008-1177-9","article-title":"S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models","volume":"199","author":"Dekeyne","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/jpet.111.187534","article-title":"S32212, a novel serotonin type 2C receptor inverse agonist\/\u03b1 2- adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization","volume":"340","author":"Dekeyne","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_185","first-page":"1120","article-title":"Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors","volume":"295","author":"Cryan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00213-007-0710-6","article-title":"Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents","volume":"192","author":"Sabb","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1527-3458.2006.00167.x","article-title":"Pharmacological profile of the 5-HT2C receptor agonist WAY-163909; therapeutic potential in multiple indications","volume":"12","author":"Dunlop","year":"2006","journal-title":"CNS Drug Rev."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/138945006775515455","article-title":"Serotonin-Dopamine Interaction as a Focus of Novel Antidepressant Drugs","volume":"7","author":"Esposito","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0924-977X(97)00055-2","article-title":"Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats","volume":"8","author":"Jenck","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.npp.1300474","article-title":"Inactivation of 5-HT2C receptors potentiates consequences of serotonin reuptake blockade","volume":"29","author":"Cremers","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/sj.npp.1301287","article-title":"Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: Mechanistic studies","volume":"32","author":"Cremers","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0924-977X(01)00078-5","article-title":"Involvement of 5-HT2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice","volume":"11","author":"Clenet","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0896-6273(02)00660-8","article-title":"Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims","volume":"34","author":"Gurevich","year":"2002","journal-title":"Neuron"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.pbb.2004.05.003","article-title":"Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats","volume":"78","author":"Yamauchi","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.neuroscience.2006.11.004","article-title":"Selective activation of 5-HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: A combined in vivo electrophysiological and neurochemical study","volume":"144","author":"Invernizzi","year":"2007","journal-title":"Neuroscience"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: Their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41380-018-0227-x","article-title":"5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy","volume":"25","author":"Demireva","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-2999(93)90767-C","article-title":"Litoxetine: A selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties","volume":"232","author":"Angel","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.2174\/138161206778522029","article-title":"5-HT3 Receptors","volume":"12","author":"Thompson","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1523\/JNEUROSCI.17-09-03157.1997","article-title":"The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon","volume":"17","author":"Morales","year":"1997","journal-title":"J. Neurosci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/cercor\/bhh097","article-title":"In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors","volume":"14","author":"Puig","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.neubiorev.2016.03.001","article-title":"5HT3 receptors: Target for new antidepressant drugs","volume":"64","author":"Gupta","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FBP.0b013e3282f3cfd4","article-title":"Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: An investigation in behaviour-based rodent models","volume":"19","author":"Ramamoorthy","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.pbb.2006.09.003","article-title":"Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test","volume":"85","author":"Bravo","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.mp.4001314","article-title":"Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor","volume":"8","author":"Eisensamer","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0306-4522(94)90384-0","article-title":"Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine","volume":"62","author":"Fan","year":"1994","journal-title":"Neuroscience"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00702-003-0074-y","article-title":"Quantitation of 5HT3 receptors in forebrain of serotonin transporter deficient mice","volume":"111","author":"Schmitt","year":"2004","journal-title":"J. Neural Transm."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(97)00115-5","article-title":"Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test","volume":"325","author":"Redrobe","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_211","first-page":"1193","article-title":"Profile of vortioxetine in the treatment of major depressive disorder: An overview of the primary and secondary literature","volume":"11","author":"Kelliny","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145712001058","article-title":"The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism","volume":"16","author":"Pehrson","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.04.008","article-title":"Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2- methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models","volume":"735","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.steroids.2015.01.021","article-title":"Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice","volume":"96","author":"Gupta","year":"2015","journal-title":"Steroids"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbr.2015.10.007","article-title":"A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system","volume":"297","author":"Gupta","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ardp.201400293","article-title":"Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: Novel 5-HT3 receptor antagonists with antidepressant-like activity","volume":"348","author":"Dhar","year":"2015","journal-title":"Arch. Pharm."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jphp.12163","article-title":"QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice","volume":"66","author":"Kurhe","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.bmcl.2013.08.072","article-title":"2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character","volume":"23","author":"Dukat","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0006-8993(97)01459-5","article-title":"The 5-HT3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats","volume":"786","author":"Nakagawa","year":"1998","journal-title":"Brain Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euroneuro.2005.10.001","article-title":"Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice","volume":"16","author":"Kos","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pbb.2014.05.024","article-title":"5HT3 receptor antagonist (ondansetron) reverses depressive behavior evoked by chronic unpredictable stress in mice: Modulation of hypothalamic-pituitary-adrenocortical and brain serotonergic system","volume":"124","author":"Gupta","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.09.041","article-title":"Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system","volume":"744","author":"Gupta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.11.009","article-title":"Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test","volume":"141","author":"Kordjazy","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2016.03.034","article-title":"Involvement of nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tropisetron and ondansetron in mice forced swimming test and tail suspension test","volume":"780","author":"Kordjazy","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1111\/bph.13857","article-title":"Response of Htr3a knockout mice to antidepressant treatment and chronic stress","volume":"174","author":"Martin","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.neuropharm.2018.02.020","article-title":"Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram","volume":"133","author":"Berrocoso","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.psc.2006.12.009","article-title":"Comorbid Alcohol and Substance Abuse Dependence in Depression: Impact on the Outcome of Antidepressant Treatment","volume":"30","author":"Ostacher","year":"2007","journal-title":"Psychiatr. Clin. N. Am."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/187152708786927886","article-title":"The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy","volume":"7","author":"Engleman","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.mp.4001490","article-title":"Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner","volume":"9","author":"Rammes","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(02)02960-6","article-title":"Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice","volume":"461","author":"Kelley","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-2999(92)90074-E","article-title":"5-HT3 receptor antagonists reverse helpless behaviour in rats","volume":"212","author":"Martin","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00213-006-0337-z","article-title":"5HT3 antagonism abolishes the emotion potentiated startle effect in humans","volume":"186","author":"Harmer","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0924-977X(03)00009-9","article-title":"Distribution of 5-HT4 receptors in the postmortem human brain\u2014An autoradiographic study using [125I]SB 207710","volume":"13","author":"Halldin","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuroimage.2010.01.054","article-title":"Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET","volume":"50","author":"Marner","year":"2010","journal-title":"Neuroimage"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1073858414561303","article-title":"Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants","volume":"22","author":"Samuels","year":"2016","journal-title":"Neuroscientist"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.2174\/13816128113196660734","article-title":"Serotonin 5-HT4 Receptors: A New Strategy for Developing Fast Acting Antidepressants?","volume":"20","author":"Vidal","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.neuint.2010.01.003","article-title":"Changes in 5-HT4 receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice","volume":"56","author":"Licht","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1471-4159.2009.06050.x","article-title":"The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration","volume":"109","author":"Licht","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/138161211795164086","article-title":"New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways","volume":"17","author":"Vidal","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: A convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_241","first-page":"1","article-title":"The effect of serotonin-targeting antidepressants on neurogenesis and neuronal maturation of the hippocampus mediated via 5-HT1A and 5-HT4 receptors","volume":"11","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1523\/JNEUROSCI.5343-08.2009","article-title":"Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation","volume":"29","author":"Flajolet","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1460-9568.2006.04943.x","article-title":"Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT 4 receptor knock-out mouse","volume":"24","author":"Conductier","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.biopsych.2004.12.023","article-title":"Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: Viral transfections, subacute and chronic treatments with 5-HT4 agonists","volume":"57","author":"Lucas","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1523\/JNEUROSCI.1656-08.2008","article-title":"Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission","volume":"28","author":"Kobayashi","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1476-5381.2010.00903.x","article-title":"Reduced signal transduction by 5-HT 4 receptors after long-term venlafaxine treatment in rats","volume":"161","author":"Vidal","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0014-2999(00)00858-X","article-title":"5-HT4 receptors do not mediate the antidepressant-like behavioral effects of fluoxetine in a modified forced swim test","volume":"409","author":"Cryan","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/npp.2013.332","article-title":"Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism","volume":"39","author":"David","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2016.08.037","article-title":"The absence of 5-HT4 receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: Adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor","volume":"111","author":"Vidal","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1021\/acschemneuro.1c00158","article-title":"5-HT4 Receptors Are Not Involved in the Effects of Fluoxetine in the Corticosterone Model of Depression","volume":"12","author":"Amigo","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.neuron.2007.07.041","article-title":"Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action","volume":"55","author":"Lucas","year":"2007","journal-title":"Neuron"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neulet.2016.01.055","article-title":"Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression","volume":"616","author":"Darcet","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuron.2007.08.011","article-title":"A Silver Bullet for the Treatment of Depression?","volume":"55","author":"Duman","year":"2007","journal-title":"Neuron"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1017\/S0033291720000604","article-title":"Translating the promise of 5HT4 receptor agonists for the treatment of depression","volume":"51","author":"Murphy","year":"2020","journal-title":"Psychol. Med."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.pharmtox.40.1.319","article-title":"5-ht 6 Receptors as Emerging Targets for Drug Discovery","volume":"40","author":"Branchek","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156802610790411036","article-title":"5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment","volume":"10","author":"Rosse","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pharmthera.2007.08.006","article-title":"Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders","volume":"117","author":"Heal","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuropharm.2005.10.002","article-title":"BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism","volume":"50","author":"Mitchell","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_259","first-page":"320","article-title":"Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs","volume":"43","author":"Monsma","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuropharm.2007.01.007","article-title":"Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression","volume":"52","author":"Nikiforuk","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2007.12.013","article-title":"The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats","volume":"582","author":"Nikiforuk","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00200","article-title":"5-HT6 receptor agonism facilitates emotional learning","volume":"6","author":"Pereira","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00213-011-2297-1","article-title":"The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration","volume":"217","author":"Nikiforuk","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00210-015-1141-2","article-title":"Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats","volume":"388","author":"Siwek","year":"2015","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.neuroscience.2007.04.045","article-title":"Acute onset by 5-HT6-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression","volume":"147","year":"2007","journal-title":"Neuroscience"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-003-0812-1","article-title":"Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat","volume":"110","author":"Dawson","year":"2003","journal-title":"J. Neural Transm."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","article-title":"Functional, molecular and pharmacological advances in 5-HT 7 receptor research","volume":"25","author":"Hedlund","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0891-0618(00)00092-2","article-title":"Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression","volume":"21","author":"Neumaier","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.neulet.2004.06.025","article-title":"Distribution of 5-HT7 receptors in the human brain: A preliminary autoradiographic study using [3H]SB-269970","volume":"367","author":"Thomas","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: An overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0893-133X(99)00041-X","article-title":"Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus","volume":"21","author":"Mullins","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_272","first-page":"1403","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuropharm.2006.04.017","article-title":"Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression","volume":"51","author":"Nikiforuk","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.107.119404","article-title":"Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents","volume":"321","author":"Bonaventure","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2006.10.001","article-title":"Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice","volume":"555","author":"Nikiforuk","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejphar.2006.09.064","article-title":"Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats","volume":"553","author":"Nikiforuk","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.112.193995","article-title":"Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder","volume":"342","author":"Bonaventure","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopsych.2006.12.011","article-title":"Inactivation of the 5-HT7 Receptor Partially Blocks Phencyclidine-Induced Disruption of Prepulse Inhibition","volume":"63","author":"Semenova","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2021.623684","article-title":"Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy","volume":"12","author":"Okubo","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pbb.2013.01.019","article-title":"Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats","volume":"105","author":"Montezinho","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Okada, M., Matsumoto, R., Yamamoto, Y., and Fukuyama, K. (2021). Effects of subchronic administrations of vortioxetine, lurasidone, and escitalopram on thalamocortical glutamatergic transmission associated with serotonin 5-ht7 receptor. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031351"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1111\/bph.13169","article-title":"The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors","volume":"172","author":"Andressen","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.4088\/JCP.10bs06601gry","article-title":"The serotonin-7 receptor as a novel therapeutic target","volume":"71","author":"Stahl","year":"2010","journal-title":"J. Clin. Psychiatry"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:48:29Z","timestamp":1760165309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":285,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22169015"],"URL":"https:\/\/doi.org\/10.3390\/ijms22169015","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}